17.04 +0.08 (0.47%)
After hours: 4:11PM EDT
|Bid||16.97 x 800|
|Ask||17.00 x 800|
|Day's Range||16.76 - 17.25|
|52 Week Range||11.03 - 32.95|
|Beta (3Y Monthly)||2.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.79|
Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders should be happy to see the share price up 23% in the last month. But that's small comfort given the dismal price performance over theRead More...
Intellia Therapeutics Inc Chief Executive John Leonard, who U.S. drug maker Bristol-Myers Squibb Co said last week was nominated by hedge fund Starboard Value LP to sit on its board, is not affiliated with the effort, an Intellia spokeswoman said on Thursday. Smoter declined to offer an explanation on how Leonard's name was included in Starboard's slate of five directors to challenge Bristol-Myers' board. Starboard declined to comment.
A targeted biotechnology ETF strategy jumped Friday after Editas Medicine (NasdaqGS: EDIT) announced fourth quarter results, revealing its latest progress toward the commercialization of its EDIT-101 drug ...
Confirmed improved non-human primate liver editing and protein reduction of greater than 95 percent in transthyretin amyloidosis program; investigational new drug application on.
CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study.
NEW YORK, Feb. 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Ahead of the opening this week, the German biotech firm signed two major partnerships with Boston-based Orchard Therapeutics and San Francisco-based Denali Therapeutics, and is also in the process of closing another partnership with a U.S. biotech company focused on hemophilia treatments.
The future of medicine is all about the personalization of medicine. That means doctors will be able to tailor treatments that fit your specific ailments. Not the general ailments of a large population of people. Today, medicine is designed to treat the most common symptoms of a disease. So everyone with that same disease will be given the exact same treatment. But considering we all have different genetic makeups, this method is clearly not ideal. That is where gene editing -- the ability to edit a human's genome -- comes into play. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The term "gene editing" oftentimes has a negative connotation. And given some of the post-apocalyptic movies that have become popular over the years, I can understand why some people are afraid. But genetic editing has so much to offer to the future of medicine. A couple of months ago, a Chinese scientist performed the first gene edit on a human by removing the gene that causes HIV in several newborns. The scientific community was not happy as most believe the science is not far enough along to verify its safety. However, the scientist proved that gene editing does have a place in the healthcare of tomorrow. There are currently more than 10,000 known monogenic diseases that do not have a cure. A monogenic disease is caused by the mutation of one gene. Yes, one single gene. Imagine being able to repair that gene and cure a disease immediately. That's exactly what science is working toward. Sickle cell disease is one of the terrible ailments that falls into this category. Today, those with this disease live with ongoing pain and the knowledge that their life will likely be shortened. But soon, science will be able to cure these people with a single procedure. * 10 Cold Weather Stocks to Heat Up Your Returns Imagine the diseases that could be irradiated through the practice of gene editing. There are many companies working toward this goal, and today I'd like to introduce you to three of the major biotech stocks to buy that focus on gene editing. Source: Shutterstock ### Crispr Therapeutics (CRSP) Crispr Therapeutics AG (NASDAQ:CRSP) is the largest of the Big Three gene-editing biotech stocks, and it has a slight lead in the race. The company made headlines in October when the Food and Drug Administration removed its clinical hold on CTX001, Crispr's gene therapy to treat sickle cell disease. Then, on Jan. 4, the FDA granted the therapy Fast Track status. This is extremely important because it allows for more frequent interaction with the FDA review team as well as a rolling review of the marketing application. Crispr Therapeutics is backed by some powerful pharma partners. Combine that with the promising treatments making headway in the United States and Europe and it is clear that this company is a great place to start investing in this innovative and inspiring trend that should make investors a lot of money. Source: Shutterstock ### Editas Medicine (EDIT) Editas Medicine (NASDAQ:EDIT) falls in the middle of the Big Three gene-editing biotech stocks to buy. It can trace its roots back to the biggest players in the industry, specifically Feng Zhang, whose affiliation with the Broad Institute has given Editas a significant leg up. The Broad Institute owns the patents to use Crispr technology in eukaryotic cells -- more complex cells that have a nucleus where the genetic material is found -- so it puts Editas in an enviable position since it has the exclusive rights to the patents for any genetic target it chooses. * 10 High-Yield Monthly Dividend Stocks This company's promising pipeline and connections make me confident that it is one of the key stocks to buy for investors interested in profiting from gene editing over the long term. Source: Pixelbay (Modified) ### Intellia (NTLA) Intellia Therapeutics (NASDAQ:NTLA) doesn't get the same amount of press as its fellow gene-editing stocks. It is also the smallest of the three, but its upside is just as huge as the other stocks to buy on this list. I say that because Intellia stands out thanks to its proprietary lipid nanoparticle delivery (LNP) technology. This takes drug therapies directly to the genes that need to be edited and does it right there rather than having to extract the gene edit it in the lab. The process has proven to be safer and more effective than the alternatives. Intellia has many irons in the fire as well as collaborations with two successful pharmaceutical companies, and I suspect it could have several therapies in FDA trials in the coming years. The key for gene-editing stocks to buy like NTLA will be to continue their partnerships and show progress, and that's exactly what it is doing. Source: Shutterstock ### Breakthrough Stocks I want to make one final note … gene-editing stocks are what I call buried treasure stocks … you could also call them breakthrough stocks since they're under the biotech frame. That means that the big returns I believe are possible take patience and time. Most investors don't have the long-term outlook that this kind of world-changing technology requires. * The 7 Best Penny Stocks to Buy If that's you, here is my suggestion: Go out and dig a big hole in your backyard. Bury these breakthrough stocks in it, and in 10 years you can dig up your buried treasure. Metaphorically speaking, of course. Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 of the Best Stocks to Buy for a Dovish Federal Reserve * 5 Best Fidelity ETFs for Retirement Savers * 7 Blue-Chip Stocks That Could Lead the Market Higher Compare Brokers The post 3 Biotech Stocks That Are Set for a Breakthrough appeared first on InvestorPlace.
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, has appointed Fred Cohen, M.D., D.Phil, F.A.C.P., to its board of directors. “We are honored to have Fred join Intellia’s board of directors.
Editas Medicine stock collapsed Tuesday — sending gene-editing stocks Crispr and Intellia also crashing — after Chief Executive Katrine Bosley said she will resign March 1.
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.
Crispr Therapeutics popped Friday after the FDA said it would expedite review of its Vertex Pharmaceuticals-partnered gene-editing sickle cell disease treatment.
NEW YORK, Dec. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Biotech stocks like CRISPR Therapeutics (NASDAQ:CRSP) are inherently risky, and inherently volatile. CRISPR stock itself, only public for a little over two years, is a good example. CRSP stock went public at $14 — and cleared $70 this year.
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced an expansion of its existing cell therapy collaboration with Novartis, to include the ex vivo development of innovative cell therapies using certain ocular stem cells. As part of the updated collaboration terms, Novartis will have the right to develop CRISPR/Cas9-based products for one or more targets using these stem cells.
Crispr Therapeutics will launch a gene-editing therapy in the U.S. in 2022, an analyst predicted Friday as he initiated coverage with a buy rating.
With more and more genetic medicine companies going commercial, Leerink turned its attention to the sector this week. The Analyst Leerink’s Mani Foroohar initiated coverage of 10 genetic medicine companies ...